昆藥集團(600422.SH):公開發行可轉債批覆到期失效
格隆匯6月16日丨昆藥集團(600422.SH)公佈,公司於2020年6月28日收到中國證券監督管理委員會出具的《關於核准昆藥集團股份有限公司公開發行可轉換公司債券的批覆》(證監許可[2020]1179號)(以下簡稱“批覆”),核准公司向社會公開發行面值總額65,300萬元可轉換公司債券,該批覆自核準發行之日(2020年6月17日)起12個月內有效。
公司在取得批覆後,積極會同中介機構推進該次可轉換公司債券發行的各項工作,但由於資本市場環境及相關法規政策發生諸多變化,導致發行條件不夠成熟,公司未能在有效期內完成公開發行可轉換公司債券事宜,該次公開發行可轉換公司債券的批覆到期失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.